Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA)
| Autor: | S J DeMaio, James A. Hearn, Gary S. Roubin, H N Bhagavan, Nicholas Lembo, D S Sgoutas, S B King rd |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Medicine (miscellaneous) Coronary Disease Coronary Angiography Placebo law.invention Double-Blind Method Randomized controlled trial Restenosis Recurrence Risk Factors law Angioplasty Internal medicine medicine Humans Vitamin E Prospective Studies Angioplasty Balloon Coronary Prospective cohort study Cardiac catheterization Nutrition and Dietetics business.industry Incidence Middle Aged medicine.disease Lipids Surgery Stenosis Apolipoproteins Cholesterol Exercise Test Cardiology Female business Follow-Up Studies |
| Zdroj: | Journal of the American College of Nutrition. 11:68-73 |
| ISSN: | 1541-1087 0731-5724 |
| DOI: | 10.1080/07315724.1992.10718198 |
| Popis: | To test whether alpha-tocopherol prevents restenosis following percutaneous transluminal coronary angioplasty (PTCA), we enrolled patients in a double-blind, placebo-controlled trial. Patients were randomized after successful PTCA to receive vitamin E in the form of dl-alpha-tocopherol, 1200 IU/day, orally vs an inactive placebo for 4 months. Patients' blood was analyzed at baseline and at 4 months post-PTCA for differences in plasma lipids, lipoproteins, apolipoproteins, alpha-tocopherol, retinol, beta-carotene and lipoperoxide concentrations. One hundred patients completed the protocol. No significant difference was found in any parameter except alpha-tocopherol level between the vitamin E group and the placebo group, verifying compliance. Follow-up cardiac catheterization was obtained in 83% of the patients receiving placebo and in 86% of the patients receiving dl-alpha-tocopherol. Including thallium and exercise stress testing, objective information was obtained for practically all the patients receiving dl-alpha-tocopherol or placebo. Restenosis was defined as the presence of a lesion with greater than or equal to 50% stenosis in a previously dilated artery segment and results were analyzed with respect to pre- and post-PTCA artery diameter, vessel diameter at follow-up, and restenosis rate. Patients receiving dl-alpha-tocopherol had a 35.5% restenosis angiographically documented vs 47.5% restenosis in patients receiving the placebo. The overall incidence of restenosis defined by an abnormal angiogram or thallium test or exercise stress test was 34.6% in patients receiving dl-alpha-tocopherol and 50% in patients receiving the placebo. This difference (p = 0.06) did not reach significance because of an inadequate sample size. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|